Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) insider James E. Flynn acquired 355,000 shares of the company’s stock in a transaction dated Tuesday, October 10th. The shares were bought at an average price of $17.00 per share, for a total transaction of $6,035,000.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Shares of Rhythm Pharmaceuticals Inc (NASDAQ RYTM) opened at 24.66 on Friday. Rhythm Pharmaceuticals Inc has a 52 week low of $23.21 and a 52 week high of $26.69. The company’s market cap is $642.98 million. The stock’s 50 day moving average price is $25.24 and its 200-day moving average price is $25.24.

COPYRIGHT VIOLATION WARNING: “Rhythm Pharmaceuticals Inc (RYTM) Insider Purchases $6,035,000.00 in Stock” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2017/10/13/rhythm-pharmaceuticals-inc-rytm-insider-purchases-6035000-00-in-stock.html.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Receive News & Stock Ratings for Rhythm Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.